div class=ts-pagebuttonPage 1button div class=ts-image a href=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5page1jpg target=_blank amp-img class=ts-thumb alt=Page 1: Parati E Alessandri G Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel Anticancer Agents Med Chem 2013 Mar 1133:523-30 src=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5thumbnails1jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 2button div class=ts-image a href=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5page2jpg target=_blank amp-img class=ts-thumb alt=Page 2: Parati E Alessandri G Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel Anticancer Agents Med Chem 2013 Mar 1133:523-30 src=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5thumbnails2jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 3button div class=ts-image a href=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5page3jpg target=_blank amp-img class=ts-thumb alt=Page 3: Parati E Alessandri G Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel Anticancer Agents Med Chem 2013 Mar 1133:523-30 src=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5thumbnails3jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 4button div class=ts-image a href=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5page4jpg target=_blank amp-img class=ts-thumb alt=Page 4: Parati E Alessandri G Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel Anticancer Agents Med Chem 2013 Mar 1133:523-30 src=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5thumbnails4jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 5button div class=ts-image a href=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5page5jpg target=_blank amp-img class=ts-thumb alt=Page 5: Parati E Alessandri G Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel Anticancer Agents Med Chem 2013 Mar 1133:523-30 src=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5thumbnails5jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 6button div class=ts-image a href=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5page6jpg target=_blank amp-img class=ts-thumb alt=Page 6: Parati E Alessandri G Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel Anticancer Agents Med Chem 2013 Mar 1133:523-30 src=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5thumbnails6jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 7button div class=ts-image a href=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5page7jpg target=_blank amp-img class=ts-thumb alt=Page 7: Parati E Alessandri G Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel Anticancer Agents Med Chem 2013 Mar 1133:523-30 src=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5thumbnails7jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 8button div class=ts-image a href=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5page8jpg target=_blank amp-img class=ts-thumb alt=Page 8: Parati E Alessandri G Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel Anticancer Agents Med Chem 2013 Mar 1133:523-30 src=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5thumbnails8jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 9button div class=ts-image a href=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5page9jpg target=_blank amp-img class=ts-thumb alt=Page 9: Parati E Alessandri G Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel Anticancer Agents Med Chem 2013 Mar 1133:523-30 src=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5thumbnails9jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 10button div class=ts-image a href=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5page10jpg target=_blank amp-img class=ts-thumb alt=Page 10: Parati E Alessandri G Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel Anticancer Agents Med Chem 2013 Mar 1133:523-30 src=https:reader042vdocumentsusreader042viewer20220410155ec6788f12b5ea1569197464html5thumbnails10jpg width=142 height=106 layout=responsive amp-imga divdiv